Approved indications (adults 18+):

• Community‑acquired pneumonia.
• Acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis (generally reserved for patients without other good options because of fluoroquinolone risks).
• Uncomplicated and complicated skin and skin‑structure infections.
• Complicated intra‑abdominal infections.
• Plague (treatment and post‑exposure prophylaxis) due to susceptible Yersinia pestis.

Common off‑label uses (evidence generally moderate): Part of multidrug regimens for drug‑resistant tuberculosis or other non‑tuberculous mycobacterial infections, and occasionally as an alternative for severe respiratory infections when first‑line agents cannot be used because of allergy or resistance.

Efficacy expectations and onset: Many people begin to feel some improvement in fever, breathing, or pain within 24–72 hours, but the full course should be completed to fully clear the infection and reduce relapse or resistance.

Typical outcomes and comparison to similar drugs: In clinical trials, moxifloxacin cures most susceptible respiratory, skin, and intra‑abdominal infections at rates comparable to other potent "respiratory" fluoroquinolones and combination regimens, with the convenience of once‑daily dosing; however, because of class safety concerns, it is often reserved for situations where safer narrow‑spectrum antibiotics are not appropriate.

Typical adult dosing (oral): 400 mg by mouth once every 24 hours. Duration is usually about 5 days for acute exacerbation of chronic bronchitis, 5–10 days for acute sinusitis or skin infections, 7–14 days for community‑acquired pneumonia, 5–14 days for complicated intra‑abdominal infections, and about 10–14 days for plague, as directed by the prescriber.

How to take: Swallow the tablet whole with a full glass of water, with or without food, at about the same time each day. Do not split, crush, or chew the tablets.

Products that interfere with absorption: Take moxifloxacin at least 4 hours before or 8 hours after antacids containing aluminum or magnesium, sucralfate, multivitamins, or supplements containing iron or zinc, or certain didanosine formulations, because these can bind the drug and reduce its effect.

Other dosing considerations: Dose adjustment is generally not required in mild to severe kidney impairment, including dialysis; however, use caution in significant liver impairment or if you have known heart rhythm problems or are taking other QT‑prolonging medicines.

Missed dose: If a dose is missed, take it as soon as remembered unless it is near the time for the next dose; if it is close, skip the missed dose and resume the regular schedule, and do not take more than one dose in a 24‑hour period.

Overdose: In case of suspected overdose, seek emergency medical attention; treatment is supportive, and activated charcoal may be used soon after ingestion to reduce absorption.

Common side effects: Nausea, diarrhea, stomach pain, headache, dizziness, trouble sleeping, and mild increases in liver enzymes are relatively common and are usually mild to moderate and appear in the first few days of therapy.

Serious or rare adverse effects (seek urgent care): Sudden tendon pain, swelling, or rupture (especially Achilles tendon); new numbness, burning, or weakness suggesting peripheral neuropathy; severe dizziness, fainting, or fast/irregular heartbeat (possible QT prolongation or arrhythmia); severe rash, swelling of face or throat, or trouble breathing (allergic reaction); confusion, hallucinations, seizures, or severe mood changes; severe watery or bloody diarrhea (possible C. difficile infection); and signs of liver injury such as yellow skin or eyes, dark urine, or severe fatigue.

Key warnings and precautions: Systemic fluoroquinolones, including moxifloxacin, carry boxed warnings for disabling and potentially permanent tendon, nerve, and central nervous system effects, and for worsening of myasthenia gravis; they have also been linked to blood‑sugar disturbances and, in some people, to an increased risk of aortic aneurysm or dissection.

Special populations: Moxifloxacin is not approved for children or adolescents under 18 because of concerns about cartilage and joint toxicity; in older adults (especially over 60) and those taking corticosteroids, the risk of tendon rupture is higher. In pregnancy, it is generally avoided unless the expected benefit clearly outweighs potential risks; during breastfeeding it enters breast milk, so clinicians may choose an alternative antibiotic or advise on short‑term interruption. No dose adjustment is usually needed in kidney impairment, but it should be used cautiously in significant liver disease or in people with known QT prolongation or electrolyte abnormalities.

Relative safety compared with other antibiotics: While effective, systemic fluoroquinolones as a class have more serious long‑term safety concerns than many older antibiotics, so guidelines now recommend using them only when other appropriate options are not available or have failed.

Side‑effect reporting and safety updates: Patients and clinicians can report suspected side effects to the FDA’s MedWatch adverse‑event reporting program and should check FDA drug‑safety communications or the product’s prescribing information for the latest warnings and guidance.

Medicines and supplements that affect absorption: Antacids containing aluminum or magnesium, sucralfate, multivitamins, and supplements that contain iron or zinc, as well as some didanosine products, can markedly reduce absorption of oral moxifloxacin and should be separated by at least 4 hours before or 8 hours after the moxifloxacin dose.

Drugs that affect heart rhythm: Because moxifloxacin can prolong the QT interval, use it cautiously or avoid it with other QT‑prolonging drugs such as class IA and III antiarrhythmics (for example amiodarone, sotalol), certain antipsychotics, tricyclic antidepressants, macrolide antibiotics, and methadone, especially in patients with low potassium or magnesium, bradycardia, or prior QT prolongation.

Other important interactions: Warfarin and related anticoagulants may have increased effects, so closer monitoring of INR or other clotting tests is advised; systemic corticosteroids increase the risk of tendonitis and tendon rupture; nonsteroidal anti‑inflammatory drugs (NSAIDs) may raise the risk of CNS stimulation and seizures; and diabetes medicines (insulin or sulfonylureas) can interact with fluoroquinolones to cause low or high blood sugar, so glucose monitoring is important.

Alcohol, food, and imaging: Food does not meaningfully reduce overall absorption, so tablets may be taken with or without meals; moderate alcohol does not cause a direct dangerous interaction but can worsen dizziness or stomach upset. There are no specific interactions with X‑ray or CT contrast agents, but overall kidney function, heart rhythm, and hydration status should still be considered.

Conditions requiring extra caution or avoidance: History of tendon disorders related to fluoroquinolones, myasthenia gravis, known QT prolongation or significant untreated arrhythmias, uncorrected low potassium or magnesium, severe liver disease, or a known aortic aneurysm are important reasons to consider alternative antibiotics or to monitor very closely if moxifloxacin must be used.

Monitoring needs: Depending on the patient and co‑medications, clinicians may monitor ECGs (for QT interval), blood glucose in people with diabetes, liver enzymes in those with hepatic risk, and signs and symptoms of tendon, nerve, or CNS toxicity during therapy.

Q: What infections is moxifloxacin by mouth usually prescribed for?
A: It is most often used in adults for community‑acquired pneumonia, acute sinus or bronchial infections, certain skin and soft‑tissue infections, complicated intra‑abdominal infections, and in some cases for plague, when the bacteria are likely to be susceptible and other options are not suitable.

Q: How quickly should I start to feel better after starting moxifloxacin?
A: Many people begin to notice improvement in fever, breathing, or pain within 1 to 3 days, but you should keep taking it for the full prescribed course even if you feel well, to fully clear the infection and reduce the risk of resistance.

Q: Why was I told not to use antacids or certain vitamins near my moxifloxacin dose?
A: Products containing magnesium, aluminum, iron, or zinc (many antacids and multivitamins) can bind moxifloxacin in the gut and prevent it from being absorbed, so doses need to be separated by several hours.

Q: Can I drink alcohol while taking moxifloxacin?
A: Alcohol does not have a major direct interaction with moxifloxacin, but it can increase dizziness or stomach upset, so many clinicians recommend limiting alcohol until you know how the medicine affects you.

Q: Is moxifloxacin safe for children or during pregnancy and breastfeeding?
A: Moxifloxacin is not approved for people under 18 years because of concerns about effects on growing joints, and in pregnancy or breastfeeding it is generally avoided unless no good alternatives are available and the expected benefit clearly outweighs potential risks.

Storage: Store tablets at room temperature (generally 68–77°F / 20–25°C), protected from excessive heat, moisture, and direct light, and keep them in the original container with the lid tightly closed.

Safety at home: Keep moxifloxacin out of sight and reach of children and pets, and do not store it in places with high humidity such as bathrooms.

Disposal: Do not flush unused tablets down the toilet or pour them into drains; instead, use a community drug take‑back program or follow your pharmacist’s instructions for safe household disposal.